Gastrointestinal tumors (GISTs) of the pancreas are extremely rare with limited individual case reports and small number of case series. Herein, we report a case of pancreatic extragastrointestinal stromal tumor (EGIST) along with literature review. A 64-year-old female patient was referred to us for treatment of an abdominal mass detected by ultrasonographic examination. The tumor was located in the periamullary region. Under a preoperative diagnosis of a duodenal GIST, we performed a pylorus preserving pancreatoduodenectomy for this lesion. Laboratory examination results were within normal ranges. On pathologic gross examination, the tumor measured at 7 cm in its greatest dimension almost entirely involved the pancreatic head. Its cut surface was rubbery and white. It was surrounded by a thin pseudocapsule and well demarcated. Histopathological examination of the specimen showed a cellular lesion with compressed pancreatic tissue at peripheral. Mitotic count was 5 per 50 high-power fields. Immunohistochemically, neoplastic cells were positive for antibodies against C-KIT (CD117), CD 34, and vimentin. However, smooth-muscle actin reactions with antibodies against S-100 or desmin were negative. Based on above findings, the tumor was finally diagnosed as GISTs originating from the pancreas. The patient has been followed up postoperatively for 72 months. There is no evidence of recurrence. Here we report this case of pancreatic EGIST presenting as a solid neoplasm along with literature review of cases previously described. Our review on pancreatic EGISTs is limited and insufficient to make a conclusion regarding its clinical features. Those manifested large masses tended to have an aggressive biological and clinical behavior. Thus, pancreatic EGISTs need to be carefully differentiated. Adequate surgical intervention is necessary for pancreatic EGISTs. 
INTRODUCTION
GISTs are the most common primary mesenchymal tumors originated from the gastrointestinal tract. These tumors occur mainly in the stomach (50-60%), small bowel (20-30%), large bowel (10%), and esophagus (5%). 1 In rare cases, these tumors are found as primary tumors outside the GI tract, such as the omentum, mesentery, retroperitoneum, and gallbladder. showed a well enhanced mass measuring 6.5×6.5 cm with central low dense lesion ( Fig. 1A and B) . Endoscopic ultrasonography (EUS) revealed a well-defined homogenous hypoechoic mass like lesion without posterior acoustic shadowing at the pancreatic head. The main pancreatic duct was mildly dilated (Fig. 1C) . EUS guided biopsy was Under a preoperative diagnosis of a duodenal GIST or pancreatic neuroendocrine tumor, we performed a pylorus preserving pancreatoduodenectomy for this lesion. On pathologic gross examination, the tumor measured at 7 cm in its greatest dimension almost entirely involved the pancreatic head. It was easily separated from duodenum. Its cut surface was rubbery and white. Surrounded by a thin pseudocapsule, it was well-demarcated ( Fig. 2A) .
Microscopically, the tumor was composed of spindle cells ( 
DISCUSSION
EGISTs arising in the pancreas are extremely rare.
Reports of pancreatic EGISTs are limited to individual case reports and small number of case series. A total of 17 patients who were confirmed as pancreatic GISTs after resection were collected in this study. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The clinicopathological features and outcomes of these cases are summarized in Table 1 . Age of these patients ranged from 30 to 74 years (median, 54.7 years; mean, 53.1 years).
Eight patients were males and nine were females. Most is high in GISTs of the esophagus and colon (95%).
However, it is relatively low in small bowel and extra-gastrointestinal sites. GISTs may also show variable positivities for other immune markers, such as SMA (30-40%), S-100 (5%), and desmin (1-25%). 19 In our review, 14 (82.4%) of 17 pancreatic EGISTs showed positivity for CD117 while 9 (52.9%) cases were positive for CD 34.
GIST exhibits a broad spectrum of clinical behaviors.
The prognosis of patients with GIST depends on the biological behavior of GIST. Fletcher et al. 1 have defined the criteria to estimate risks of aggressive behavior and metastasis of GIST using tumor dimension (cm) and mitotic count (/50 HPF). According to their criteria, GISTs are divided into risk categories of very low (＜2 cm, ＜5/50 4 Yamaura et al. 5 Krska et al. 6 Daum et al. 7 Showalter et al. 8 Trabelsi et al. 9 Padhi et al. 10 Saif et al. 11 Rao et al. 12 Čečka et al. 13 Vij et al. 14 Yang et al. 15 Kim et al. 16 Tian et al. 17 Elgeidie et al. 18 Our case GISTs. 20 Systemic regional lymphadenectomy is not generally considered because lymph node metastasis is rare (prevalence of about 1%). 21 Response rates of GISTs to conventional chemotherapy and radiotherapy are 10% and 5%, respectively.
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Adjuvant treatment with imatinib can be provided in order to enhance the possibility of curing the cancer by eradicating microscopic lesions that might remain after complete resection of visual tumors. 19 DeMattero et al. 22 have reported that most recurrence of GIST will occur within 24 months after resection, with liver and peritoneum being the most common site of recurrence. Reith et al. 23 reported that 39% of patients with EGIST developed metastatic disease or died from tu- 
